The approval of the waiver of offer obligations allows major shareholders and certain members of RVL Pharmaceuticals' management team to acquire ordinary shares without incurring an obligation to make a general offer to other shareholders. This may lead to an increase in shareholding by these parties, which could potentially impact the stock price. However, the short-term impact is uncertain as it depends on the actions taken by the major shareholders and management.